The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human CDH1 (UniProt P12830) — Functional Annotation of E‑cadherin

1. Target verification (gene/protein identity)

The requested target (UniProt P12830) corresponds to human E‑cadherin, encoded by CDH1 on chromosome 16q22.1, a canonical epithelial classical cadherin and core component of adherens junctions (ghosh2024realtimeanalysisof pages 15-19, samardali2025acomprehensiveliterature pages 1-2). The structure described in recent mechanistic work (single-pass transmembrane glycoprotein with five extracellular cadherin domains) is consistent with a classical cadherin family protein and matches the UniProt-provided cadherin domain context (ghosh2024realtimeanalysisof pages 15-19).

2. Key concepts, definitions, and current understanding (core function)

2.1 What CDH1/E‑cadherin is

E‑cadherin is a calcium-dependent cell–cell adhesion molecule that organizes epithelial tissue architecture by mediating homophilic adhesion and supporting epithelial integrity and polarity (ghosh2024realtimeanalysisof pages 15-19, samardali2025acomprehensiveliterature pages 2-3).

2.2 Domain architecture and molecular mechanism of adhesion

Recent mechanistic description emphasizes that E‑cadherin is a single-pass transmembrane glycoprotein with extracellular, transmembrane, and intracellular regions, and that its extracellular portion contains five cadherin repeats (EC1–EC5) with calcium-binding sites (ghosh2024realtimeanalysisof pages 15-19).

At the molecular level, homophilic trans-binding is driven primarily by the EC1 domain and proceeds through an X-dimer intermediate followed by formation of a stable strand-swapped dimer, in which a tryptophan side chain from one EC1 inserts into a hydrophobic pocket of the opposing EC1 (ghosh2024realtimeanalysisof pages 15-19). This “strand swapping” mechanism is a central concept in current structural understanding of type I classical cadherin adhesion (ghosh2024realtimeanalysisof pages 15-19).

2.3 Subcellular localization and adherens junction organization

In epithelia, E‑cadherin is enriched at the plasma membrane and concentrates at adherens junctions where it contributes to epithelial sheet cohesion and tissue architecture (ghosh2024realtimeanalysisof pages 15-19, melo2023theecmand pages 9-10).

2.4 Binding partners: the cadherin–catenin complex

A defining functional property of E‑cadherin is that its cytoplasmic region couples adhesive contacts to the actin cytoskeleton via catenins. Experimental/biophysical synthesis emphasizes anchoring through β‑catenin and α‑catenin, enabling transmission of actomyosin forces across junctions (ghosh2024realtimeanalysisof pages 27-29). Broader mechanistic synthesis also highlights interaction with p120‑catenin, and how changes in E‑cadherin availability can alter β‑catenin and p120‑catenin signaling states (samardali2025acomprehensiveliterature pages 7-8).

3. Pathways and signaling context (functional consequences beyond adhesion)

3.1 Mechanotransduction at cell–cell junctions

Beyond static adhesion, E‑cadherin junctions are described as part of a mechanosensitive scaffold: E‑cadherin-based adhesions transmit actomyosin-generated pulling forces through β‑catenin/α‑catenin anchorage, and junction stability can be limited by cytoskeletal anchorage rather than cadherin–cadherin binding strength (ghosh2024realtimeanalysisof pages 27-29). This supports a current view of adherens junctions as force-bearing and force-sensing structures, not merely “glue” (ghosh2024realtimeanalysisof pages 27-29).

3.2 Crosstalk with Wnt/β‑catenin and Rho-family GTPases

Loss or cleavage/downregulation of E‑cadherin can release constraints on β‑catenin signaling; a synthesis of cancer-related mechanisms describes that E‑cadherin loss can permit β‑catenin nuclear translocation with Wnt pathway activation (samardali2025acomprehensiveliterature pages 7-8). The same synthesis notes that redistribution of p120‑catenin can influence RhoA/Rac1 signaling with downstream cytoskeletal and mechanical consequences (samardali2025acomprehensiveliterature pages 7-8).

3.3 EMT (epithelial–mesenchymal transition)

Reduction of E‑cadherin is repeatedly emphasized as central to EMT-associated loss of epithelial cohesion and increased migratory/invasive behavior. A mechanistic synthesis reports that EMT programs repress E‑cadherin and that such loss contributes to invasion and metastasis (samardali2025acomprehensiveliterature pages 7-8, samardali2025acomprehensiveliterature pages 3-4). A 2024 mechanistic work likewise frames E‑cadherin downregulation as a hallmark of EMT and cancer cell motility changes (ghosh2024realtimeanalysisof pages 27-29).

4. Recent developments and latest research (prioritizing 2023–2024)

4.1 2023: Tissue architecture/ECM context shapes invasion caused by E‑cadherin dysfunction

A 2023 peer-reviewed study combined in vitro extrusion assays using HDGC-associated E‑cadherin mutants with mathematical/computational modeling and concluded that early invasion is not only driven by weakened cell–cell adhesion but is also strongly determined by ECM attachment and 3D tissue architecture (e.g., gland-like cylindrical geometry), which can increase basal extrusion/invasive ability (Melo et al., 2023-11; https://doi.org/10.1038/s42003-023-05482-x) (melo2023theecmand pages 9-10). This line of work represents a shift from viewing CDH1 loss as sufficient for invasion to a multi-factor framework integrating tissue mechanics and geometry (melo2023theecmand pages 9-10).

4.2 2024: Real-time / minimal-system analyses of junction formation emphasize biophysical control

A 2024 mechanistic analysis using a minimal reconstituted framework (as described in the retrieved text) emphasizes the detailed adhesion mechanism (EC1 X-dimer → strand-swap), actin coupling via catenins, and junction expansion constraints due to lateral membrane pressure/crowding effects, reinforcing a view of E‑cadherin junctions as an emergent physical system supporting mechanotransduction (ghosh2024realtimeanalysisof pages 15-19, ghosh2024realtimeanalysisof pages 27-29). While the venue metadata in the retrieved text is incomplete, the mechanistic content is consistent with modern junction biophysics and complements the 2023 ECM/architecture invasion emphasis (ghosh2024realtimeanalysisof pages 15-19, ghosh2024realtimeanalysisof pages 27-29).

4.3 2024: Clinical genetics—re-estimation of penetrance and management shift toward selective surveillance

A 2024 narrative review in Hereditary Cancer in Clinical Practice synthesizes newer penetrance estimates and explicitly argues that the risk of advanced diffuse gastric cancer (DGC) in CDH1 pathogenic variant carriers is lower than historically estimated, motivating increased consideration of endoscopic surveillance for selected carriers (van der Sluis et al., 2024-10; https://doi.org/10.1186/s13053-024-00293-5) (sluis2024currentadvancesand pages 2-4, sluis2024currentadvancesand pages 1-2).

5. Current applications and real-world implementations

5.1 Genetic testing and risk-reduction decisions in hereditary diffuse gastric cancer (HDGC)

Germline CDH1 pathogenic variants are a primary cause of HDGC, and clinical management has historically included prophylactic total gastrectomy (PTG) due to poor detectability and prognosis of invasive DGC (samardali2025acomprehensiveliterature pages 6-7, sluis2024currentadvancesand pages 1-2).

However, 2024 synthesis highlights a contemporary management challenge: ~30% (around one third) of CDH1 variant carriers decline PTG, often due to major quality-of-life sequelae (e.g., postoperative complications and chronic symptoms) (sluis2024currentadvancesand pages 2-4, sluis2024currentadvancesand pages 1-2). The same review lists common long-term PTG impacts, including substantial mean weight loss (~15–23%) and gastrointestinal/psychosocial effects, which are central to shared decision-making (sluis2024currentadvancesand pages 2-4).

5.2 Endoscopic surveillance protocols (implementation details)

For carriers who defer PTG, expert-center surveillance is recommended; IGCLC-style protocols include targeted biopsies plus ~28–30 random biopsies (sluis2024currentadvancesand pages 2-4). A key implementation issue is sensitivity: detection of early pT1a signet ring cell carcinoma (SRCC) by endoscopy is variable (~20–60% reported in the 2024 synthesis), and modeling suggests random biopsy counts needed for high sensitivity may be impractical (e.g., ~1800 biopsies estimated for 90% detection), supporting an emphasis on targeted lesions and improved recognition frameworks (sluis2024currentadvancesand pages 2-4).

The 2024 review further reports that, in some analyses, targeted biopsies have substantially higher yield than random biopsies (11% vs 0.9%), reinforcing movement toward targeted sampling plus structured histologic/endoscopic interpretation rather than attempting exhaustive random sampling (sluis2024currentadvancesand pages 2-4).

5.3 CDH1/E‑cadherin in oncology practice (biomarker/pathology context)

E‑cadherin loss is widely used in tumor pathology contexts as a marker of altered epithelial differentiation/adhesion and is mechanistically linked to invasive phenotypes (ghosh2024realtimeanalysisof pages 27-29, samardali2025acomprehensiveliterature pages 3-4). OpenTargets disease–target associations further reflect extensive disease relevance of CDH1 in cancers (e.g., breast adenocarcinoma, endometrial carcinoma, ovarian cancer) and in “CDH1-related diffuse gastric and lobular breast cancer syndrome” as a disease entity (OpenTargets; accessed via tool output) (OpenTargets Search: -CDH1).

6. Expert synthesis and analysis (authoritative interpretations)

6.1 E‑cadherin loss is necessary but not sufficient for invasive progression

The 2023 Communications Biology work provides explicit evidence that invasion in HDGC models emerges from interplay between defective cell–cell junctions, ECM attachment, and 3D tissue architecture, rather than from loss of adhesion alone (melo2023theecmand pages 9-10). Functionally, this reframes CDH1 as a gatekeeper whose loss creates vulnerability to invasion that is realized under permissive tissue/ECM contexts (melo2023theecmand pages 9-10).

6.2 Clinical penetrance is heterogeneous; management is moving toward risk stratification

The 2024 HDGC management review synthesizes multiple penetrance estimates, describing a shift from historical ~80% lifetime DGC risk to more recent cohort-derived estimates such as 37–42% (men) and 22–33% (women) in some US cohorts, and even 7–10% irrespective of family history in a more recent study; it also notes that risk can be higher (e.g., ~38%) in high-penetrance families (sluis2024currentadvancesand pages 2-4). The same review highlights that microscopic SRCC foci are common in PTG specimens, yet many individuals may never develop advanced disease, supporting a move away from uniform PTG recommendations toward more individualized approaches (sluis2024currentadvancesand pages 4-5, sluis2024currentadvancesand pages 1-2).

7. Key statistics and data (recent, practice-relevant)

7.1 Penetrance / risk (2024 synthesis)

From the 2024 Hereditary Cancer in Clinical Practice review (publication: 2024-10; https://doi.org/10.1186/s13053-024-00293-5):
- Advanced DGC lifetime risk estimates have been revised downward and vary by cohort: 37–42% (men) and 22–33% (women) in some datasets; a recent study reported 7–10% irrespective of family history; risk may be ~38% in high-penetrance families (sluis2024currentadvancesand pages 2-4).
- Lifetime lobular breast cancer risk in women: 37–55% (sluis2024currentadvancesand pages 2-4, sluis2024currentadvancesand pages 1-2).
- PTG refusal/decline: ~30% (sluis2024currentadvancesand pages 2-4, sluis2024currentadvancesand pages 1-2).
- Endoscopic SRCC detection variability: ~20–60% in PTG/HDGC surveillance contexts (sluis2024currentadvancesand pages 2-4).
- Targeted vs random biopsy yield: 11% vs 0.9% (sluis2024currentadvancesand pages 2-4).

7.2 Mechanistic structure/function (2024 mechanistic description)

Key mechanistic facts for functional annotation include: 5 extracellular cadherin repeats (EC1–EC5), EC1-driven homophilic strand-swap dimerization, and intracellular coupling to actin via catenins (ghosh2024realtimeanalysisof pages 15-19, ghosh2024realtimeanalysisof pages 27-29).

8. Summary of functional annotation (concise)

CDH1 (UniProt P12830) encodes E‑cadherin, the canonical epithelial classical cadherin that mediates calcium-dependent homophilic cell–cell adhesion at adherens junctions and couples intercellular contacts to the actin cytoskeleton through catenins, enabling epithelial cohesion and mechanotransduction (ghosh2024realtimeanalysisof pages 15-19, ghosh2024realtimeanalysisof pages 27-29). Loss or functional impairment of E‑cadherin contributes to EMT-associated invasion and alters signaling (including Wnt/β‑catenin and Rho-family GTPase pathways), and germline CDH1 pathogenic variants underlie HDGC, where contemporary (2024) literature supports more individualized management balancing PTG morbidity against surveillance strategies given revised (often lower) estimates of advanced cancer risk (samardali2025acomprehensiveliterature pages 7-8, sluis2024currentadvancesand pages 2-4).

Evidence summary table

Table: This table summarizes core functional-annotation facts for human CDH1/E-cadherin (UniProt P12830), including structure, mechanism, localization, partners, pathways, and clinical relevance. It is useful as a compact, evidence-backed reference for the final research report.

References

1. (ghosh2024realtimeanalysisof pages 15-19): S Ghosh. Real-time analysis of e-cadherin mediated junction formation in cancer cells using a minimal reconstituted system. Unknown journal, 2024.

2. (samardali2025acomprehensiveliterature pages 1-2): Malik Samardali, Jehad Samardaly, and Ibrahim Shanti. A comprehensive literature review of the cdh1 mutation and its role in gastric cancer. Cureus, May 2025. URL: https://doi.org/10.7759/cureus.85072, doi:10.7759/cureus.85072. This article has 2 citations.

3. (samardali2025acomprehensiveliterature pages 2-3): Malik Samardali, Jehad Samardaly, and Ibrahim Shanti. A comprehensive literature review of the cdh1 mutation and its role in gastric cancer. Cureus, May 2025. URL: https://doi.org/10.7759/cureus.85072, doi:10.7759/cureus.85072. This article has 2 citations.

4. (melo2023theecmand pages 9-10): Soraia Melo, Pilar Guerrero, Maurício Moreira Soares, José Rafael Bordin, Fátima Carneiro, Patrícia Carneiro, Maria Beatriz Dias, João Carvalho, Joana Figueiredo, Raquel Seruca, and Rui D. M. Travasso. The ecm and tissue architecture are major determinants of early invasion mediated by e-cadherin dysfunction. Communications Biology, Nov 2023. URL: https://doi.org/10.1038/s42003-023-05482-x, doi:10.1038/s42003-023-05482-x. This article has 15 citations and is from a peer-reviewed journal.

5. (ghosh2024realtimeanalysisof pages 27-29): S Ghosh. Real-time analysis of e-cadherin mediated junction formation in cancer cells using a minimal reconstituted system. Unknown journal, 2024.

6. (samardali2025acomprehensiveliterature pages 7-8): Malik Samardali, Jehad Samardaly, and Ibrahim Shanti. A comprehensive literature review of the cdh1 mutation and its role in gastric cancer. Cureus, May 2025. URL: https://doi.org/10.7759/cureus.85072, doi:10.7759/cureus.85072. This article has 2 citations.

7. (samardali2025acomprehensiveliterature pages 3-4): Malik Samardali, Jehad Samardaly, and Ibrahim Shanti. A comprehensive literature review of the cdh1 mutation and its role in gastric cancer. Cureus, May 2025. URL: https://doi.org/10.7759/cureus.85072, doi:10.7759/cureus.85072. This article has 2 citations.

8. (sluis2024currentadvancesand pages 2-4): L. van der Sluis, J.M. van Dieren, R.S. van der Post, and T.M. Bisseling. Current advances and challenges in managing hereditary diffuse gastric cancer (hdgc): a narrative review. Hereditary Cancer in Clinical Practice, Oct 2024. URL: https://doi.org/10.1186/s13053-024-00293-5, doi:10.1186/s13053-024-00293-5. This article has 11 citations and is from a peer-reviewed journal.

9. (sluis2024currentadvancesand pages 1-2): L. van der Sluis, J.M. van Dieren, R.S. van der Post, and T.M. Bisseling. Current advances and challenges in managing hereditary diffuse gastric cancer (hdgc): a narrative review. Hereditary Cancer in Clinical Practice, Oct 2024. URL: https://doi.org/10.1186/s13053-024-00293-5, doi:10.1186/s13053-024-00293-5. This article has 11 citations and is from a peer-reviewed journal.

10. (samardali2025acomprehensiveliterature pages 6-7): Malik Samardali, Jehad Samardaly, and Ibrahim Shanti. A comprehensive literature review of the cdh1 mutation and its role in gastric cancer. Cureus, May 2025. URL: https://doi.org/10.7759/cureus.85072, doi:10.7759/cureus.85072. This article has 2 citations.

11. (OpenTargets Search: -CDH1): Open Targets Query (-CDH1, 30 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

12. (sluis2024currentadvancesand pages 4-5): L. van der Sluis, J.M. van Dieren, R.S. van der Post, and T.M. Bisseling. Current advances and challenges in managing hereditary diffuse gastric cancer (hdgc): a narrative review. Hereditary Cancer in Clinical Practice, Oct 2024. URL: https://doi.org/10.1186/s13053-024-00293-5, doi:10.1186/s13053-024-00293-5. This article has 11 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Citations

1. ghosh2024realtimeanalysisof pages 15-19
2. ghosh2024realtimeanalysisof pages 27-29
3. samardali2025acomprehensiveliterature pages 7-8
4. melo2023theecmand pages 9-10
5. sluis2024currentadvancesand pages 2-4
6. samardali2025acomprehensiveliterature pages 1-2
7. samardali2025acomprehensiveliterature pages 2-3
8. samardali2025acomprehensiveliterature pages 3-4
9. sluis2024currentadvancesand pages 1-2
10. samardali2025acomprehensiveliterature pages 6-7
11. sluis2024currentadvancesand pages 4-5
12. https://doi.org/10.1038/s42003-023-05482-x
13. https://doi.org/10.1186/s13053-024-00293-5
14. https://doi.org/10.7759/cureus.85072,
15. https://doi.org/10.1038/s42003-023-05482-x,
16. https://doi.org/10.1186/s13053-024-00293-5,